News | June 02, 2021
Lasa Supergenerics FY21 profit up 521%
Revenues from operations for FY21 stood at Rs. 202.38 crore as compared to 167.27 crore, up by 21%
Revenues from operations for FY21 stood at Rs. 202.38 crore as compared to 167.27 crore, up by 21%
Aurobindo has one of the most enduring generics ecosystems among peers
The company has posted net profit of Rs.147.78 crores for the 12 months period ended March 31, 2021
The company's operating revenue for Q4 FY21 was Rs. 330.2 crore
7.94 crore doses were made available to the states in May 2021
The company reported total income of Rs.24774.63 crores during the 12 months period ended March 31, 2021
Cadila's ZyCov-D (DNA-based vaccine) is undergoing phase III trials.
The company has posted net profit of Rs.1140.01 crores during FY 2020-21
It posted net profit of Rs.60.96 crores for the 12 months period ended March 31, 2021
For the year ended March 31, 2021, consolidated revenue was at Rs. 10,943.9 crores as against Rs. 10,641 crores, recording an increase of 2.8% over the previous corresponding period
Subscribe To Our Newsletter & Stay Updated
